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Abstract
Background: After the concept of healthcare associated pneumonia (HCAP) was introduced in 2005 by the
American Thoracic Society/Infectious Disease Society of America (ATS/IDSA), pneumonia in hemodialysis patients
has been classified as HCAP. Even though there are several risk factors and scoring systems of drug-resistant
pathogens (DRPs) in HCAP, the risk factors for DRPs in hemodialysis-associated pneumonia are unclear.
Methods: Patients who were admitted to our tertiary care hospital from January 2005 to December 2010 were
screened by a discharge diagnosis of pneumonia. Patients were enrolled if they fulfilled the definition of HCAP
according to the 2005 ATS/IDSA guidelines.
Results: A total of 530 subjects were diagnosed with HCAP, of whom 48 (9.1 %) received regular hemodialysis (HD
group) and the other 482 did not (non-HD group). The most common pathogens in HD group were Pseudomonas
aeruginosa and methicillin resistant Staphylococcus aureus (MRSA). There was a similar distribution of Gram-negative
bacilli infections between the two groups except for Haemophilus influenzae and Citrobacter species. The incidence
of DRPs was not significantly different between the two groups (HD vs. non-HD, 35.4 vs. 39.2 %, p = 0.607). Wound
care, severe pneumonia and an age of more than 70 years were significant risk factors for DRPs. The area under the
operating cure of predicting DRPs was 0.727 (0.575–0.879, p = 0.01).
Conclusion: P. aeruginosa and MRSA were the most important pathogens in hemodialysis-associated pneumonia.
Wound care, severe pneumonia and old age were significant risk factors for DRPs.
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Background
End-stage renal disease (ESRD) has a great impact on
global health care. Taiwan had the highest prevalence of
ESRD in 2010 according to the United States (US) renal
data system 2013 annual report [1], and of these cases,
around 90 % underwent hemodialysis [2]. Pneumonia is
associated with significant morbidity and mortality in
hemodialysis patients. An US study reported that around
one third of hemodialysis patients suffered from pneu-
monia during a 5-year period [3].
The American Thoracic Society/Infectious Disease So-
ciety of America (ATS/IDSA) introduced the concept of
healthcare-associated pneumonia (HCAP) in 2005, and
their guidelines included the risk of drug-resistant path-
ogens (DRPs) and recommended broad spectrum antibi-
otics therapy as the treatment of hospital-acquired
pneumonia [4]. Hemodialysis patients were close to
healthcare facilities. Therefore, according to the 2005
ATS/IDSA guidelines, hemodialysis-associated pneumo-
nia (HDAP) could be considered as a part of HCAP.
However, HCAP is a heterogeneous disease entity. Sev-
eral studies have reported risk factors for DRPs in
HCAP, including previous antibiotics exposure, poor ac-
tivity of daily living or prior residence in a long-term
care facility [5]. Although it is clear that hemodialysis
patients are at a high risk of blood-stream infections
with DRPs [6], the impact of hemodialysis on the risk of
DRPs have some arguments. Some studies suggested
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hemodialysis was one of risk factors for DRPs whereas
many others failed to show this association [5, 7, 8].
There might be some risk factors of DRPs specific to
patients with hemodialysis. Therefore, we conducted this
retrospective study to identify risk factors for DRPs, and
to review the demographic and clinical characteristics
and microorganisms between HDAP and HCAP.
Methods
Patients who were admitted to the Far Eastern Memorial
Hospital, an 800-bed tertiary care hospital in Taiwan,
from January 2005 to December 2010 were screened by
the primary discharge diagnosis of pneumonia (Inter-
national Classification of Diseases codes 482, 485, and
486). The medical records and radiological findings were
reviewed to confirm the diagnosis of pneumonia by the
following criteria: new or worsening respiratory symp-
toms; fever, leukocytosis or leucopenia; new or worsen-
ing infiltrates on chest plain films pneumonia. Among
these pneumonia patients, they were enrolled if they ful-
filled the criteria for HCAP, which were defined as fol-
lows: patients who had been hospitalized in an acute
care hospital for two or more days within the past 90 days;
residents of a nursing home or long-term care facility; re-
cipients of recent intravenous antibiotic therapy, chemo-
therapy or wound care within the past 30 days; or patients
who attended a hospital or hemodialysis clinic. The pa-
tients who had been transferred in from other hospitals
were excluded as their hospital course could not be sure.
Demographic, clinical and microbiological data were col-
lected from medical records. The Institutional Review
Board of Far Eastern Memorial Hospital approved this
study (IRB 102013-E).
A daily steroid dose of more than 10 mg for more than
3 months was defined as steroid use [9]. Chronic kidney
disease was defined as an estimated glomerular filtration
rate below 30 ml/min without the need for hemodialysis.
Active chemotherapy was chemotherapy within the past
60 days for an underlying malignancy. If there were no
data of arterial blood gas, oxygen saturation as measured
by pulse oximetry (SpO2) below 90 % in room air was
taken to imply a partial pressure of oxygen below
60 mmHg. Data on causative pathogens were obtained
from cultures of respiratory tract secretions such as
sputum, tracheal and bronchial aspiration, and/or the
cultures of sterile specimens within 72 h of admission
including blood or pleural effusion. Legionella pneu-
mophila and Streptococcus pneumoniae urine antigen
tests were also recorded if these exams were checked.
The criterion of causative pathogens obtaining from
sputum culture was white cell count > 10 per high
power field. DRPs were defined as pathogens resistant
to community-acquired pneumonia antibiotics regimens
such as ampicillin-sulbactam, ceftriaxone, cefotaxime and
respiratory quinolone (moxifloxacin or gemifloxacin) In
the other words, DRPs included Pseudomonas aeruginosa
(P. aeruginosa), Acinetobacter species, Stenotrophomonas
maltophilia (S. maltophilia), methicillin resistant Staphylo-
coccus aureus (MRSA), and Enterobacteriaceae not
sensitive to third generation cephalosporins. The initial
antibiotic treatment was classified as being inappropriate
if they were not active against the identified pathogens
based on in vitro susceptibility testing [10]. β-lactams,
quinolones, cephalosporins and carbapenems against P.
aeruginosa, and anti-MRSA chemotherapy were included
as broad-spectrum antibiotics. The pneumonia severity
index (PSI) was calculated according to the Pneumonia
Patient Outcomes Research Team cohort study for
community-acquired pneumonia [11]. Severity was di-
vided into four groups as follows: PSI class II, III, IV, and
V as ≤ 70, 71–90, 91–130, > 130, respectively.
All data were expressed as mean ± SD (standard devi-
ation of the mean) unless otherwise stated. Statistical ana-
lysis was performed using SPSS version 18 software (SPSS
Inc., Chicago, IL, USA). Continuous data were compared
using the Student’s t-test, and categorical data including
demographics, outcomes, antibiotics and microbiology
were compared using chi-square distribution (Mann-
Whitney test). Multivariate analysis of risk factors was
used by general linear model. Comparisons of the clinical
characteristics of PSI groups were performed using
ANOVA. Significance was taken as p < 0.05.
Results
A total of 530 subjects were diagnosed with HCAP, of
whom 48 (9.1 %) received regular hemodialysis therapy
(HD group), and the other 482 did not (non-HD
group). The clinical characteristics are shown in
Table 1. The HD group was significantly younger than
the non-HD group (68.3 ± 11.3 vs. 75.8 ± 12.8 years, p
= 0.001). Pneumonia was less severe in the HD group
(p = 0.008), and more patients were PSI III but less
were PSI IV and V in the HD group. The incidence of
diabetes mellitus was higher in the HD group than in
the non-HD group (70.8 vs. 38.6 %, p < 0.001), however
the non-HD group had more comorbidities including
cerebrovascular illnesses, malignancy, and chronic ob-
structive pulmonary disease than the HD group (52.1
vs. 27.1 %, p = 0.001; 28.2 vs. 10.4 %, p = 0.008; and 37.3
vs. 22.9 %, p = 0.047, respectively). Immunosuppression
therapy including chemotherapy and steroid therapy
were more frequently in the non-HD group (p = 0.024
and 0.008).
Only one subject in the HD group had bacteremia,
which was Klebsiella pneumoniae (K. pneumoniae). The
causative microorganisms are shown in Table 2. The
yield rate of pathogenic organisms was 43.8 % in the HD
group. The incidence of S. aureus was similar between
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the HD and non-HD groups (10.4 vs. 9.3 %). There were
also similar distributions of Gram-negative bacilli be-
tween the two groups except for Haemophilus influenzae
(H. influenzae) and Citrobacter species. None of the pa-
tients in the HD group had H. influenzae, however 42
patients (8.7 %) in the non-HD group did (p = 0.033).
Citrobacter species were more frequently isolated in the
HD group, although the difference was not statistically
significant (4.2 vs. 1 %, p = 0.07).
The incidence of DRPs was not significantly differ-
ent between the HD and non-HD groups (35.4 vs.
39.2 %, p = 0.607). The rates of DRPs stratified by PSI
are shown as Fig. 1. In HD group, there were no sig-
nificant differences in the rate of DRPs among PSI
groups, although there was a trend towards an in-
creasing number of DRPs infections as the PSI in-
creased (p = 0.16). However, there was a significantly
higher risk of DRPs in those with PSI V compared to
those with PSV II-IV (p = 0.047).
Shown in Fig. 2, the rate of inappropriate antibiotics
use was not significantly different between the HD and
non-HD groups (41.7 vs. 46.3 %, p = 0.542). However,
the in-hospital mortality rate of the HD group was sig-
nificantly lower than that of the non-HD group (2.1 vs.
18.7 %, p = 0.004).
Multivariate analysis showed that wound care (OR: 4.73,
95 % of CI: 1.13–19.7, p = 0.026), PSI V (OR: 3.49, 95 % of
CI: 1.08–12.1) and an age of more than 70 years (OR:
3.81, 95 % of CI: 1.07–13.5, p = 0.035) were risk factors for
DRPs. Using these three risk factors, the area under the
receiver operating curve for predicting DRPs was 0.727
(0.575–0.879, p = 0.01) (Fig. 3). In addition, MRSA was an
important pathogen in the patients with HDAP who re-
ceived wound care compared to those who did not receive
wound care (36.4 vs. 2.7 %, p = 0.001).
Discussion
The results showed that there were heterogeneous clin-
ical characteristics but similar patterns of pathogens be-
tween HD and non-HD groups. The leading pathogens
were P. aeruginosa and MRSA in the patients with
HDAP. The significant risk factors to predict DRPs in
the patients with HDAP were wound care, old age (more
than 70 years) and PSI V. Wound care not only pre-
dicted Gram-negative DRPs but also MRSA.
Even though hemodialysis pneumonia was classified as
a sub-type of HCAP in the 2005 ATS/IDSA guidelines,
the risk of DRPs in HDAP was not clearly evaluated at
that time. Only some indirect evidence supports the role
of DRPs and especially MRSA in HDAP [12, 13].
Table 1 Demographic and clinical characteristics
Total (N = 530) HD(N = 48) Non-HD (N = 482) p
Age(years) 75.1 ± 12.8 68.3 ± 11.3* 75.8 ± 12.8 <0.001
Sex(M/F) 349/181 25/23 326/156
PSI 129.6 ± 33.5 116.8 ± 34.9 130.8 ± 33.2
PSI group 0.008
PSI II 15(2.8) 4(8.3) 11(2.3)
PSI III 51(9.6) 11(22.3)* 40(8.3)
PSI IV 195(36.8) 14(29.2)* 181(37.6)
PSI V 269(50.8) 19(39.6)* 250(51.9)
ICU n(%) 116 (21.9) 7(14.6) 109(22.6) 0.2
Admission within 90 d n(%) 317(59.8) 14(29.2)* 303(62.9) <0.005
Nursing home n(%) 224 (42.3) 10(20.8)* 214(44.4) 0.002
Antibiotics within 90 d n(%) 232 (43.8) 13(27.1)* 219(45.4) 0.015
Active chemotherapy n(%) 47 (8.9) 0* 47(9.8) 0.024
Steroid use n(%) 63(11.9) 0* 63(13.1) 0.008
Wound care n(%) 103 (19.4) 11(22.9) 92(19.1) 0.528
CVA n(%) 264 (49.8) 13(27.1)* 251(52.1) 0.001
Malignancy n(%) 140(26.4) 5(10.4)* 135(28.2) 0.008
DM n(%) 220 (41.5) 34(70.8)* 186(38.6) <0.005
Heart failure n(%) 84(15.8) 9(18.8) 75(15.6) 0.564
COPD n(%) 191(36) 11(22.9)* 180(37.3) 0.047
Liver cirrhosis 20 (3.8) 0 20(4.1) 0.151
PSI, pneumonia severity index, ICU intensive care unit, CVA cerebrovascular illnesses, DM diabetes mellitus, CKD chronic renal disease, COPD chronic obstructive
pulmonary disease, * p < 0.05 HD vs. non-HD
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Therefore, Attridge and colleagues suggested that HDAP
is considered to be a sub-type of HCAP more by infer-
ence than evidence [14]. There is still much debate with
regards to HDAP pathogens. A large retrospective stud-
ies in the United States (US) showed that the most com-
mon Gram-positive bacteria was S. pneumoniae [3],
even though the role of S. aureus, and especially MRSA
is well known in HDAP [15–18]. Furthermore, Pop-
Vicas suggested that hemodialysis was not a risk factor
for drug-resistant Gram-negative bacteria [19]. In
addition, several other studies have suggested the CAP
pathogens such as K. pneumoniae and H. influenzae play
important roles in HDAP [3, 15, 16]. P. aeruginosa didn’t
have the significant impact on HDAP as it suggested in
the ATS/IDSA guideline [4]. In contrast, some studies
have shown that the DRPs in HDAP are similar to those
in nosocomial pneumonia [20, 21]. And the risk of
multi-drug resistance has been reported to be higher in
patients with HDAP than community-acquired pneumo-
nia pathogens such as K. pneumoniae [22]. Our results
proved that P. aeruginosa and MRSA were the most
common pathogens in HDAP, supporting the HCAP
concept. The differences in these studies may be associ-
ated with different methodologies, geographic factors
and local infection control.
PSI was a well-accepted severity scoring system of
community acquired pneumonia(CAP) [23]. Khawaja re-
ported that DRPs such as P. aeruginosa and S. aureus
were important pathogens in severe CAP [24]. Falcone
and his colleagues proposed that PSI was not as useful
in HCAP as in CAP to evaluate outcome and severity
[25]. But Falcone reported higher incidence of DRPs in
PSI IV and V in community onset pneumonia including
HCAP and CAP [26]. Some studies also reported that a
critical illness in need of intensive care or mechanic ven-
tilation was a risk factor for DRPs [8, 27, 28]. The similar
findings were shown in our study, which showed an up-
ward trend of DRPs incidence as PSI class increased.
DRPs incidence in PSI V was significantly higher than
PSI II–IV.
Our results showed a lower in-hospital mortality rate
in the patients with HDAP than in non-HD patients.
The patients with HDAP were younger, had less cerebro-
vascular disease and shorter stay in long-term care facil-
ities. These characteristics of the patients with HDAP in
our study imply a better functional status than non-HD
patients. Ewig and colleagues proposed the importance
of functional status and daily living activity levels in
pneumonia treatment and outcomes [29]. According to
PSI, the patients with HDAP had less severe disease.
Therefore, it was not surprising that the patients with
HDAP had better outcomes.
There are still concerns about which extensive board-
spectrum antibiotics should be use for patients with
HCAP. Several studies have investigated the risks of
DRPs in HCAP with the aim of preventing the overuse
of board-spectrum antibiotics. The same issue exists in
HDAP. Taylor and colleagues suggested that it was not
essential to use antibiotics to cover nosocomial patho-
gens in every HDAP patient, and that conventional CAP
antibiotic therapy may be safe for some hemodialysis pa-
tients [17]. However, the inadequate use of empirical an-
tibiotics may increase the mortality rate [30]. Therefore,
identifying the risk factors for DPRs is also important in
patients with HDAP. Muraya and colleagues reported
that age had a marked impact on the prognosis of
hemodialysis patients with pneumonia [18]. Our results
showed that wound care and severe disease (PSI V) were
additional risk factors for DPRs in addition to age. The
Table 2 Causative pathogens of hemodialysis-associated








Unknown pathogens n(%) 27(56.2) 217(45.0)
Causative pathogens sensitive to CAP antibiotics regimen
S. pneumoniae n(%) 16 (3.0) 0(0) 16(3.3)
MSSA n(%) 13 (2.5) 0(0) 13(2.7)
β-Streptococcus n(%) 15 (2.8) 2(4.2) 13(2.7)
K. pneumoniae n(%) 42(7.9) 2(4.2) 40(8.3)
E. coli n(%) 18(3.4) 3(6.3) 23(4.8)
H. influenzae n(%) 42(7.9) 0(0) 42(8.7)*
M.catarrhalis n(%) 1(0.2) 0(0) 1(0.2)
M. morganii n(%) 5(0.9) 0(0) 5(1)
P. mirabilis n(%) 23(4.3) 0(0) 23(4.8)
E. cloacae n(%) 16(3.0) 3(6.3) 13(2.7)
S. marcescens n(%) 33(6.2) 2(4.2) 31(6.4)
Causative pathogens resistant to CAP antibiotics regimen
MRSA n(%) 37 (7.0) 5(10.4) 32(6.6)
K. pneumoniae n(%) 2 (0.4) 0 (0) 2 (0.4)
E. coli n(%) 8 (1.5) 0 (0) 0 (0)
P. mirabilis n(%) 2 (0.4) 0 (0) 2(0.4)
P. aeruginosa n(%) 129(24.3) 8(16.7) 121(25.1)
A. baumannii n(%) 25(3.7) 2(4.2) 23(4.7)
S. maltophila n(%) 22(4.2) 1(2.1) 21(4.4)
Citrobacter species n(%) 7(1.3) 2(4.2)a 5(1.0)b
CAP community acquired pneumonia, S. pneumoniae Streptococcus
pneumoniae, MSSA methicillin sensitive Staphylococcus aureus, MRSA methicillin
resistant Staphylococcus aureus, K. pneumoniae Klebsiella pneumoniae, E. coli
Escherichia coli, H. influenzae Haemophilus influenzae, M. catarrhalis Moraxella
catarrhalis, P. mirabilis Proteus mirabilis, E. cloacae Enterobacter cloacae, S.
marcescens Serratia marcescens, P. aeruginosa Pseudomonas aeruginosa, A.
baumannii Acinetobacter baumannii, S. maltophilia Stenotrophomonas
maltophilia.* p < 0.05 HD vs. non-HD
a both were Citrobacter freundii
b Three were Citrobacter freundii; two were Citrobacter diversus
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area under the receiver operating characteristic curve of
these three risk factors was 0.727, which is comparable
with the studies about risk factors of DRPs in HCAP pa-
tients by Shorr and Aliberti [8, 31]. Another reported risk
factor associated with DRPs colonization in patients with
chronic hemodialysis is antibiotic exposure for more than
7 days in the previous 3 months [19]. The risk factors re-
ported in previous studies did not show a significant cor-
relation with DRPs in the current study. This may be
because first-aid in outpatient hemodialysis clinics is read-
ily available, and that partial treatment with oral antibi-
otics was common before admission.
Citrobacter species are commonly found in water, soil
and the intestinal tract of human [32]. Citrobacter infec-
tions usually occur in debilitated, hospitalized patients,
with multiple comorbidities [33]. Respiratory tract infec-
tions are also common for Citrobacter infection [33–35].
We found an incidence of Citrobacter species of 4.2 % in
HDAP, ranking as the fourth common Gram-negative
bacteria pathogens, which was less than that of P.
aeruginosa, Escherichia coli and Enterobacter cloacae.
To the best of our knowledge, this is the first study
to report that Citrobacter species are a major HDAP
pathogen, even though it had a close relationship with
Fig. 1 The incidence of drug-resistant pathogens in HDAP, non-hemodialysis HCAP and various PSI groups of HDAP. a There was no significant
difference in the incidence of DRPs between the HDAP and non-HD HDAP groups. b In HD group, there was a trend towards an increasing number
of DRPs as the PSI group increased (p = 0.16). HDAP: hemodialysis associated pneumonia, HCAP: healthcare associated pneumonia, HD: hemodialysis,
DRPs: drug-resistant pathogens, PSI: pneumonia severity index
Fig. 2 The rate of inappropriate antibiotics and in-hospital mortality rate in patients with HDAP and non-hemodialysis HCAP. There was no significant
difference in the rate of inappropriate antibiotic use between the HDAP and non-HD groups. However, the in-hospital mortality rate was lower in the
HD group than in the non-HD group (p < 0.001). HDAP: hemodialysis associated pneumonia, HCAP: healthcare associated pneumonia, HD: hemodialysis
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healthcare facilities. This finding may be associated
with geographic factors, and further studies are
needed to clarify the relationship between Citrobacter
infection and HDAP.
There were some limitations about this study. It
was a single-center retrospective study, and therefore
the results may be limited and not generalizable to
other regions. The cases number of HD group was
small so that it might have negative impact on the
power of the study. Furthermore, 56.2 % of HD group
and 45 % of non-HD group had no definite patho-
gens to identify. Although the findings were compat-
ible with clinical experiences and previous studies
about pneumonia pathogens, it might limit the inter-
pretation of microbiologic data. It needs a large-
scaled prospective study to focus on the epidemiology
of HDAP.
Conclusions
In spite of the small sample size, our results provide
additional information with regards to the pathogens
than large-scale retrospective studies that did not
mostly identify causative pathogens [3, 16]. The re-
ported pathogens in this study confirmed the ATS/
IDSA guidelines [4]. The significant risk factors for
DRPs in patients with HDAP were old age, wound
care and severe pneumonia. Taking these into consid-
eration, the unnecessary use of broad spectrum anti-
biotics may be avoided.
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